title: Chronic oral ascorbic acid therapy worsens skeletal muscle metabolism in patients with chronic heart failure.
abstract: BACKGROUND
  Chronic heart failure (CHF) is associated with abnormalities of skeletal muscle metabolism. This may be due to impaired oxygen delivery as a result of endothelial dysfunction.
  
  
  OBJECTIVE
  We postulated that ascorbic acid would improve oxygen delivery to exercising muscle and improve skeletal muscle metabolism.
  
  
  METHODS
  We studied skeletal muscle metabolism using (31)P magnetic resonance spectroscopy in 39 CHF patients. Endothelial function was assessed by changes in pulse wave velocity. Subjects were randomised to receive 4 g ascorbic acid daily for 4 weeks in a placebo-controlled double-blind study.
  
  
  RESULTS
  Ascorbic acid significantly increased phosphocreatine utilization during exercise. In addition, glycolytic ATP synthesis increased in the ascorbic acid group (change in rate of ATP synthesis at 1 min -0.21+/-0.76 with placebo, 2.06+/-0.60 following ascorbic acid; p<0.05). Phosphocreatine and ADP recovery after exercise were not changed. The fall in pulse wave velocity during reactive hyperaemia was increased by ascorbic acid from -6.3+/-2.6% to -12.1+/-2.0% (p<0.05).
  
  
  CONCLUSIONS
  These findings suggest that ascorbic acid increased both phosphocreatine utilization and glycolytic ATP synthesis during exercise in patients with CHF implying worsened skeletal muscle metabolism despite improvements in endothelial function.
authors.affiliation: Bristol Heart Institute, Bristol University, Bristol, UK. drangus@doctors.org.uk <drangus@doctors.org.uk>
authors.forename: Angus K
authors.initials: AK
authors.lastname: Nightingale
authors.forename: Jenifer G
authors.initials: JG
authors.lastname: Crilley
authors.forename: Nicholas C
authors.initials: NC
authors.lastname: Pegge
authors.forename: Ernie A
authors.initials: EA
authors.lastname: Boehm
authors.forename: Catherine
authors.initials: C
authors.lastname: Mumford
authors.forename: Doris J
authors.initials: DJ
authors.lastname: Taylor
authors.forename: Peter
authors.initials: P
authors.lastname: Styles
authors.forename: Kieran
authors.initials: K
authors.lastname: Clarke
authors.forename: Michael P
authors.initials: MP
authors.lastname: Frenneaux
mesh_terms: D000255:Adenosine Triphosphate / Q000096:biosynthesis; D000368:Aged; D001205:Ascorbic Acid / Q000097:blood / Q000627:therapeutic use*; D002908:Chronic Disease; D004311:Double-Blind Method; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D005260:Female; D006333:Heart Failure / Q000378:metabolism* / Q000503:physiopathology; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000378:metabolism; D010725:Phosphocreatine / Q000378:metabolism; D006113:United Kingdom
chemical_list: D010725:Phosphocreatine; D000255:Adenosine Triphosphate; D001205:Ascorbic Acid